Nanjing Hanxin Licenses AC02 ACTH Analogue to Amphastar for $151 Million US/Canada Deal
Nanjing Hanxin Pharmaceutical Technology Co., Ltd. has entered a licensing agreement with Amphastar Pharmaceuticals, Inc....
Amphastar Pharmaceuticals
Ajinomoto and Amphastar Ink Licensing Pact for Oncology and wAMD Drug Candidates
Nanjing Ajinomoto Bio-Pharma Services and Amphastar Pharmaceuticals (NASDAQ: AMPH) announced on August 12, 2025, the...